Business description: Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Number of employees: 5,007

Sales by Activity: Evotec SE

Fiscal Period: December20192020202120222023

EVT Execute

420M 489M 610M 736M 739M

EVT Innovate

94.33M 106M 147M 205M 267M

Transition

14.5M 21.84M - - -

Intersegment Elimination

-82.7M -116M -139M -189M -224M
See all business segments

Geographical breakdown of sales: Evotec SE

Fiscal Period: December20192020202120222023

USA

195M 248M - - 459M

Rest of the World

82.68M 77.71M - - 95.15M

United Kingdom

77.9M 93.99M - - 86.37M

Switzerland

- - - - 64.92M

Germany

27.98M 44.32M - - 34.13M

France

62.83M 37.06M - - 32M
See all geographic segments

Managers: Evotec SE

Director TitleAgeSince
Chief Executive Officer - 30/06/2024
Director of Finance/CFO 51 31/03/2023
Chief Operating Officer 54 31/12/2018
Chief Tech/Sci/R&D Officer 60 31/08/2010
Investor Relations Contact - -
See EVOTEC SE governance

Members of the board: Evotec SE

Manager TitleAgeSince
Chairman 64 14/06/2021
Director/Board Member 56 18/06/2019
Director/Board Member 62 31/05/2021
Director/Board Member 41 21/06/2022
Director/Board Member 57 09/06/2024
Director/Board Member 68 09/06/2024
Composition of the Board of Directors

Shareholders: Evotec SE

NameEquities%Valuation
Excalibur Luxco SARL
9.986 %
17,730,913 9.986 % 136 M €
Novo Holdings A/S (Investment Company)
8.410 %
14,931,858 8.410 % 115 M €
Mubadala Investment Co. (Investment Company)
6.467 %
11,481,502 6.467 % 88 M €
T. Rowe Price International Ltd.
5.557 %
9,866,813 5.557 % 76 M €
Global Alpha Capital Management Ltd.
3.062 %
5,437,444 3.062 % 42 M €
NameEquities%Valuation
Novo Holdings A/S (Investment Company)
16.70 %
14,829,842 16.70 % 57 M €
Mubadala Investment Co. (Investment Company)
5.179 %
4,597,701 5.179 % 18 M €
Wellington Trust Co., NA
2.967 %
2,634,434 2.967 % 10 M €
DCF Advisers LLC
0.2445 %
217,055 0.2445 % 840 003 €
Mediolanum International Funds Ltd.
0.1581 %
140,383 0.1581 % 543 282 €
List of EVOTEC SE shareholders

Company details: Evotec SE

Evotec SE

Manfred Eigen Campus Essener Bogen 7

22419, Hamburg

+49 40 560 81 0

http://evotec.com
address Evotec SE(EVT)

Group companies: Evotec SE

NameCategory and Sector
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Pharmaceuticals: Major
See all subsidiaries

Other Biotechnology & Medical Research

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.79%-0.68%-53.39%-77.95%1.64B
+0.42%-0.80%+56.02%-26.05%43B
+1.35%+0.89%-6.01%-22.98%36.78B
-0.50%-3.69%+12.49%-7.48%26.11B
+3.81%+3.43%-18.99%-18.23%17.95B
-1.26%-0.22%+54.04%+95.88%16.5B
+3.49%+3.20%-44.86%-83.25%17.1B
+0.84%-1.13%+12.83%-36.35%11.84B
+2.40%+2.91%+25.93%+71.01%10.87B
+0.14%-3.64%-4.42%-45.41%9.81B
Average +0.72%+0.11%+3.36%-15.08% 19.16B
Weighted average by Cap. +0.92%+0.13%+13.57%-13.37%
See all sector performances
Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart EVOTEC-SEMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
8.770EUR
Average target price
11.04EUR
Spread / Average Target
+25.86%
Consensus

Quarterly revenue - Rate of surprise